Clinical trial
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With…
NCT00338728 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00338728 |
|---|---|
| Title | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer |
| Official title | Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8 |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate, Letrozole |
| Enrollment | 59 |
| Start date | Oct 3, 2003 |
| Primary completion | Nov 27, 2018 |
| Completion | Nov 27, 2018 |
| First posted | Jun 20, 2006 |
| Last update posted | Jan 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: